Early research (Phase 1)Study completedNCT00000822
What this trial is testing
A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells
Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 46